{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T23:48:45Z","timestamp":1770940125659,"version":"3.50.1"},"reference-count":36,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>To compare demographics, clinical characteristics, health care resource utilization (HCRU), treatment duration, and overall survival (OS) with enzalutamide (ENZA) or abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) in England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>This retrospective study analyzed data from the Cancer Analysis System database on patients receiving ENZA or AA (January 2014-March 2020) for chemotherapy-na\u00efve mCRPC (mCRPC was the only funded indication for ENZA\/AA during study period). Baseline characteristics were assessed using standardized mean difference (SMD) (&lt;0.1: balanced); differences were adjusted for using propensity score weighting (PSW). Cox proportional hazard models were used for OS and treatment duration. Number needed to treat was calculated from HCRU incidence rate ratios (IRRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Overall, 8,485 patients were included (ENZA, 5,330; AA, 3,155). Diabetes mellitus was more prevalent in the ENZA group (SMD, 0.12) at treatment initiation. HCRU was comparable between groups before treatment initiation (SMD &lt; 0.1), but HCRU IRR after treatment initiation favored ENZA. Compared with AA, ENZA was associated with significantly fewer inpatient stays, outpatient or accident and emergency (A&amp;E) visits, and hospitalization days (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .01), and significantly lower likelihood of treatment discontinuation (adjusted hazard ratio [aHR], 0.90 [95% CI, 0.86 to 0.96];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .01) and mortality risk (aHR, 0.92 [95% CI, 0.87 to 0.98];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .010). Assuming 8 months' treatment and comparable groups through PSW, 1.9 inpatient admissions, 17.3 outpatient visits, 1.4 A&amp;E visits, and 19.5 hospitalization days could be avoided per 10 patients on ENZA versus AA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Patients with mCRPC on ENZA or AA had generally similar baseline characteristics apart from diabetes prevalence. ENZA was associated with longer OS and treatment duration, and lower HCRU after treatment initiation than AA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-24-01045","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T15:59:11Z","timestamp":1745251151000},"page":"274-284","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Attributes and Health Care Resource Utilization of Patients on Enzalutamide or Abiraterone for Metastatic Castration-Resistant Cancer in England"],"prefix":"10.1200","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8525-0310","authenticated-orcid":false,"given":"Amit","family":"Bahl","sequence":"first","affiliation":[{"name":"Bristol Cancer Institute, University Hospitals Bristol, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3410-1435","authenticated-orcid":false,"given":"Rita","family":"Faria","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd, Surrey, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[{"name":"Schleswig-Holstein University Hospital, L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-7983","authenticated-orcid":false,"given":"Gert","family":"Attard","sequence":"additional","affiliation":[{"name":"University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Snijder","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd, Surrey, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Sodatonou","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd, Surrey, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sari","family":"Stark","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd, Surrey, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Pranzo","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd, Surrey, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Martins","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd, Surrey, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1510-1675","authenticated-orcid":false,"given":"Nigel","family":"Rozario","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd, Surrey, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8770-7982","authenticated-orcid":false,"given":"Jess","family":"Ridsdale-Smith","sequence":"additional","affiliation":[{"name":"IQVIA Inc, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Chilelli","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd, Surrey, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","volume-title":"Abiraterone for Castration-Resistant Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen","author":"National Institute for Health and Care Excellence","unstructured":"National Institute for Health and Care Excellence: Abiraterone for Castration-Resistant Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen. https:\/\/www.nice.org.uk\/guidance\/ta259"},{"key":"e_1_3_7_3_2","volume-title":"Enzalutamide for Metastatic Hormone-Relapsed Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen","author":"National Institute for Health and Care Excellence","year":"2014","unstructured":"National Institute for Health and Care Excellence: Enzalutamide for Metastatic Hormone-Relapsed Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen. 2014. https:\/\/www.nice.org.uk\/Guidance\/TA316"},{"key":"e_1_3_7_4_2","volume-title":"Enzalutamide for Treating Metastatic Hormone-Relapsed Prostate Cancer Before Chemotherapy Is Indicated. Technology Appraisal Guidance [TA377]","author":"National Institute for Health and Care Excellence","year":"2016","unstructured":"National Institute for Health and Care Excellence: Enzalutamide for Treating Metastatic Hormone-Relapsed Prostate Cancer Before Chemotherapy Is Indicated. Technology Appraisal Guidance [TA377]. 2016. https:\/\/www.nice.org.uk\/guidance\/ta377"},{"key":"e_1_3_7_5_2","volume-title":"Abiraterone for Treating Metastatic Hormone-Relapsed Prostate Cancer Before Chemotherapy Is Indicated. Technology Appraisal Guidance [TA387]","author":"National Institue for Health and Care Excellence","unstructured":"National Institue for Health and Care Excellence: Abiraterone for Treating Metastatic Hormone-Relapsed Prostate Cancer Before Chemotherapy Is Indicated. Technology Appraisal Guidance [TA387]. https:\/\/www.nice.org.uk\/guidance\/ta387"},{"key":"e_1_3_7_6_2","volume-title":"Abiraterone 500 mg Film-Coated Tablets\u2014Summary of Product Characteristics (SmPC)","author":"Electronic Medicines Compendium","unstructured":"Electronic Medicines Compendium: Abiraterone 500 mg Film-Coated Tablets\u2014Summary of Product Characteristics (SmPC). https:\/\/www.medicines.org.uk\/emc\/product\/14010\/smpc"},{"key":"e_1_3_7_7_2","volume-title":"Prednisolone 5 mg Tablets\u2014Summary of Product Characteristics (SmPC)","author":"Electronic Medicines Compendium","unstructured":"Electronic Medicines Compendium: Prednisolone 5 mg Tablets\u2014Summary of Product Characteristics (SmPC). https:\/\/www.medicines.org.uk\/emc\/product\/2427\/smpc"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2016.02.010"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0774-1"},{"key":"e_1_3_7_10_2","volume-title":"Xtandi 40 mg Film Coated Tablets (Great Britain)\u2014Summary of Product Characteristics (SmPC)","author":"Electronic Medicines Compendium","year":"2024","unstructured":"Electronic Medicines Compendium: Xtandi 40 mg Film Coated Tablets (Great Britain)\u2014Summary of Product Characteristics (SmPC). 2024. https:\/\/www.medicines.org.uk\/emc\/product\/10318\/smpc"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244462"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1108937"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00816-0"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.669236"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.07.031"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00588-5"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153773"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00318-3"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz076"},{"key":"e_1_3_7_21_2","volume-title":"Enzalutamide for Treating Hormone-Sensitive Metastatic Prostate Cancer","author":"National Institute for Health and Care Excellence","year":"2021","unstructured":"National Institute for Health and Care Excellence: Enzalutamide for Treating Hormone-Sensitive Metastatic Prostate Cancer. 2021. https:\/\/www.nice.org.uk\/guidance\/ta712"},{"key":"e_1_3_7_22_2","article-title":"Systemic anti-cancer therapy (SACT) data set","author":"NHS England","year":"2019","unstructured":"NHS England: Systemic anti-cancer therapy (SACT) data set. Cancer Drugs Fund Methodol, 2019. https:\/\/digital.nhs.uk\/ndrs\/data\/data-sets\/sact\/sact-cdf-methodologies","journal-title":"Cancer Drugs Fund Methodol"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5657"},{"key":"e_1_3_7_24_2","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen J","year":"1988","unstructured":"Cohen J: Statistical Power Analysis for the Behavioral Sciences (ed 2). New York, NY, Routledge, 1988","edition":"2"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.18865\/ed.30.S1.185"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.08.009"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14972"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35472"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-1683(24)01257-6"},{"key":"e_1_3_7_31_2","volume-title":"Managing NHS Backlogs and Waiting Times in England: Thirty-Eighth Report of Session 2022\u201323","author":"House of Commons Committee of Public Accounts","year":"2023","unstructured":"House of Commons Committee of Public Accounts: Managing NHS Backlogs and Waiting Times in England: Thirty-Eighth Report of Session 2022\u201323. 2023. https:\/\/committees.parliament.uk\/publications\/34131\/documents\/187908\/default\/"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01260-x"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10029-017-1713-9"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02301-5"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdr054"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05280-y"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100261"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-24-01045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:59:44Z","timestamp":1770937184000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-24-01045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1200\/OP-24-01045"],"URL":"https:\/\/doi.org\/10.1200\/op-24-01045","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2024-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}